person
Frank K.
- Country
- Germany
- Department
- Medizinische Klinik und Poliklinik 1, Bereich Hämatologie,
Research Overview
assignment
9
Clinical Trials ·
- A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, VERSUS INVESTIGATOR’S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1)
- Randomized European Trial of Autologous Transplantation with Rituximab, Ibrutinib, and Ara-C Induction in Generalized Mantle Cell Lymphoma
- Phase 3 Study of Acalabrutinib with R-CHOP in Patients Aged ≤75 with Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma
location_city
1
Research Sites
Data & Insights
medical_services
Primary Speciality
Main therapeutic area
handshake
Return Partnerships
Recurring site collaborations
137
Sites with multiple studies
Has run more than one trial at 137 of 318 partner sites.
Specializations
Lymphoma Research Focus
The investigator specializes in treating various forms of B-cell lymphomas, with particular emphasis on developing innovative therapeutic approaches for both newly diagnosed and relapsed/refractory cases.
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Follicular Lymphoma
- Mantle Cell Lymphoma
- Primary CNS Lymphoma
Treatment Approaches
The investigator focuses on evaluating advanced therapeutic strategies including combination therapies and targeted treatments.
- Novel Agent Combinations
- Immunotherapy Applications
- High-Dose Chemotherapy
- Stem Cell Transplantation
Clinical Innovation
Key areas of therapeutic investigation include targeted antibody treatments and personalized medicine approaches for lymphoma patients.
- Novel Antibody Therapies
- Risk-Adapted Treatment Strategies
- Age-Adjusted Protocols
- Maintenance Therapy Optimization
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.